Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 4/20 | 0.71 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.71 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14908001 | 0.84 | PI4KA (0.72) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| SCHEMBL1998927 | 0.83 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| SCHEMBL896095 | 0.83 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| SCHEMBL5740769 | 0.83 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| SCHEMBL8712264 | 0.83 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| SCHEMBL30352942 | 0.83 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| SCHEMBL14983401 | 0.83 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| Methane SCHEMBL10551641 | 0.82 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| SCHEMBL4572213 | 0.80 | CYP2C19 (0.74) | PI4KAPI4K2BPI4K2API4KBMEN1 | |
| SCHEMBL31569297 | 0.80 | CYP2C19 (0.74) | PI4KAPI4K2BPI4K2API4KBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0577725-A4 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIV FLORIDA (US) | 1996-04-17 | — | — | EP | claimed |
| EP-0577725-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1994-01-12 | — | — | EP | claimed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | claimed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160250233-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9353051-B2 | Antiviral drugs for treatment or prevention of dengue infection | SIGA TECHNOLOGIES, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2928470-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2015-10-14 | — | — | EP | disclosed |
| CN-101743008-A | Antiviral agent for treating or preventing dengue fever infection | SIGA TECHNOLOGIES INC | 2010-06-16 | — | — | CN | disclosed |
| EP-2148678-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | Siga Technologies, Inc. (US) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008147962-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20060252040-A1 | Strand specific detection and quantification | ANWAR AZLINDA | 2006-11-09 | — | — | US | disclosed |
| EP-1537240-A2 | STRAND SPECIFIC DETECTION AND QUANTIFICATION | Johns Hopkins Singapore Pte Ltd (SG) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022784-A2 | STRAND SPECIFIC DETECTION AND QUANTIFICATION | JOHNS HOPKINS SINGAPORE PTE LTD (SG) | 2004-03-18 | — | — | WO | disclosed |
| EP-0577725-A4 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIV FLORIDA (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0577725-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1994-01-12 | — | — | EP | disclosed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | PI4KA 2626/4885PI4K2B 2944/4885PI4K2A 2508/4885 |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | PI4KA 2778/4885PI4K2B 2994/4885PI4K2A 2594/4885 |
| US-20160250233-A1 | ANTIVIRAL DRUGS FOR TREATMENT OR PREVENTION OF DENGUE INFECTION | EIF2AK2, HAVCR2, SNRPE | PI4KA 1610/4885PI4K2B 2100/4885PI4K2A 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.